This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Jan;16(1):7-9.

doi: 10.1016/S1470-2045(14)71184-2. Epub 2014 Dec 11.

IBIS-I tamoxifen update: maturity brings questions

Rowan T Chlebowski¹

Affiliations

Affiliation

¹ Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, 1024 W Carson Street, Torrance, CA 90502, USA. Electronic address: rowanchlebowski@gmail.com.

PMID: 25497695
DOI: 10.1016/S1470-2045(14)71184-2

Free article

Comment

IBIS-I tamoxifen update: maturity brings questions

Rowan T Chlebowski. Lancet Oncol. 2015 Jan.

Free article

. 2015 Jan;16(1):7-9.

doi: 10.1016/S1470-2045(14)71184-2. Epub 2014 Dec 11.

Author

Rowan T Chlebowski¹

Affiliation

¹ Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, 1024 W Carson Street, Torrance, CA 90502, USA. Electronic address: rowanchlebowski@gmail.com.

PMID: 25497695
DOI: 10.1016/S1470-2045(14)71184-2

No abstract available

PubMed Disclaimer

Comment on

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators. Cuzick J, et al. Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25497694 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information